Diabetes CV Trials May Look Different From SAVOR, EXAMINE In Future
Executive Summary
Outcomes trials of AstraZeneca’s saxagliptin and Takeda’s alogliptin provide reassurance on cardiovascular risks but raise other safety concerns that are difficult to interpret due to the studies’ high-risk populations and ischemia-focused endpoints.
You may also be interested in...
At Liraglutide Panel Review, A Call For CV Studies To Look Beyond MACE
If cardiovascular studies are required for non-cardiac drugs, they should be focused on specific signals of heart-related concern that may not include ischemic events, advisory committee cardiologists say during review of Novo Nordisk’s Saxenda for obesity.
Will CV Verdicts For Onglyza, Nesina Cause FDA To Change Its Tune On Antidiabetic Safety?
Large outcomes studies showed neither cardiovascular harm nor benefit with BMS/AstraZeneca’s saxagliptin or Takeda’s alogliptin, prompting some commenters to question whether FDA’s blanket approach to CV safety for all antidiabetic agents needs adjustment.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.